Literature DB >> 29468728

European Surveillance System on Contact Allergies (ESSCA): polysensitization, 2009-2014.

Daan Dittmar1, Wolfgang Uter2, Andrea Bauer3, Ana B Fortina4, Andreas J Bircher5, Magdalena Czarnecka-Operacz6, Aleksandra Dugonik7, Peter Elsner8, Rosella Gallo9, Sharizan A Ghaffar10, Anna Giménez-Arnau11, Graham A Johnston12, Beata Kręcisz13, Francesca L Filon14, Thomas Rustemeyer15, Anna Sadowska-Przytocka6, Javier Sánchez-Pérez16, Axel Schnuch17, Dagmar Simon18, Radoslaw Spiewak19, Philipp Spring20, Maria T Corradin21, Skaidra Valiukevičienė22,23, Marko Vok24, Elke Weisshaar25, Mark Wilkinson26, Marie L Schuttelaar1.   

Abstract

BACKGROUND: Polysensitization, defined as being allergic to three or more haptens from the European baseline series, is considered to reflect increased susceptibility to developing a contact allergy, and is likely to be associated with an impaired quality of life.
OBJECTIVES: To evaluate the prevalences of polysensitization across Europe and to analyse factors associated with polysensitization.
METHODS: Patch test data collected by the European Surveillance System on Contact Allergies (ESSCA; www.essca-dc.org) in consecutively patch tested patients from January 2009 to December 2014, comprising 11 countries and 57 departments, were retrospectively analysed.
RESULTS: A total of 86 416 patients were available for analysis, showing a standardized prevalence of polysensitization of 7.02%, ranging from 12.7% (Austria) to 4.6% (Italy). Allergen pairs with the strongest association are reported for the total population, for South Europe, and for North/Central Europe. Overall, polysensitized patients showed a higher percentage of extreme (+++) positive patch test reactions than oligosensitized patients. Female sex, occupational dermatitis and age > 40 years were risk factors for polysensitization.
CONCLUSIONS: The varying prevalences of polysensitization across Europe most likely reflect differences in patient characteristics and referral patterns between departments. Known risk factors for polysensitization are confirmed in a European dermatitis population.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  clinical epidemiology; contact allergy; patch test; polysensitization

Mesh:

Substances:

Year:  2018        PMID: 29468728     DOI: 10.1111/cod.12966

Source DB:  PubMed          Journal:  Contact Dermatitis        ISSN: 0105-1873            Impact factor:   6.600


  4 in total

1.  Contact dermatitis: Clinical practice findings from a single tertiary referral hospital, a 4-Year retrospective study.

Authors:  Giovanni Sedó-Mejía; Andrés Soto-Rodríguez; Caridad Pino-García; Alfredo Sanabria-Castro; Olga Patricia Monge-Ortega
Journal:  World Allergy Organ J       Date:  2020-08-11       Impact factor: 4.084

Review 2.  Immunological Processes Driving IgE Sensitisation and Disease Development in Males and Females.

Authors:  Jonatan Leffler; Philip A Stumbles; Deborah H Strickland
Journal:  Int J Mol Sci       Date:  2018-05-23       Impact factor: 5.923

3.  European Surveillance System on Contact Allergies (ESSCA): Contact allergies in relation to body sites in patients with allergic contact dermatitis.

Authors:  Jart A F Oosterhaven; Wolfgang Uter; Werner Aberer; José C Armario-Hita; Barbara K Ballmer-Weber; Andrea Bauer; Magdalena Czarnecka-Operacz; Peter Elsner; Juan García-Gavín; Ana M Giménez-Arnau; Swen M John; Beata Kręcisz; Vera Mahler; Thomas Rustemeyer; Anna Sadowska-Przytocka; Javier Sánchez-Pérez; Dagmar Simon; Skaidra Valiukevičienė; Elke Weisshaar; Marie L A Schuttelaar
Journal:  Contact Dermatitis       Date:  2019-01-14       Impact factor: 6.600

4.  Analysis of Prevalence and Risk Factors of Contact Sensitization with respect to the Occupational Profiles in a Greek Patient Cohort: A Retrospective Analysis of a Greek Referral Centre and Future Perspectives.

Authors:  Anna Tagka; George I Lambrou; George K Matsopoulos; Despoina Fytili; Daphne Mirkopoulou; Alexandra Katsarou; Argyro Chatziioannou; Alexandros Stratigos
Journal:  Biomed Res Int       Date:  2021-05-06       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.